The effect of infliximab on extraintestinal manifestations of Crohn's disease

Rheumatology International

Volumn 25, Issue 6, 2005, Pages 406-410

  Kaufman, Ilana ^a,b   Caspi, Dan ^a   Yeshurun, Dror ^a   Dotan, Iris ^a   Yaron, Michael ^a   Elkayam, Ori ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Extraintestinal manifestations; Infliximab

Indexed keywords

INFLIXIMAB;

ADULT; AGED; APHTHOUS STOMATITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DRUG INFUSION; ERYTHEMA NODOSUM; EYE INJURY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; IRON DEFICIENCY ANEMIA; LIVER DISEASE; LUMBAR SPINE; MALE; MEGALOBLASTIC ANEMIA; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM EXAMINATION; MUSCULOSKELETAL SYSTEM INFLAMMATION; NEPHROLITHIASIS; PAIN; PHYSICAL EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUESTIONNAIRE; SACROILIITIS; SKIN ULCER; SYNOVITIS; THORAX; THROMBOCYTOSIS; THROMBOSIS; TREATMENT OUTCOME; ULCERATIVE COLITIS; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; PYODERMA GANGRENOSUM; QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23944510297     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0467-8     Document Type: Article

References (29)

1. Bernstein CN, Blanchard JF, Rawsthorne P et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116-1122
2. Wollbeim FA (2001) Enteropathic arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley's textbook of rheumatology, 6th edn. Saunders, Philadelphia, pp 1081-1088
3. Salvarani C, Viachonikolis IG, van der Heijde DM et al (2001) Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 36:1307-1313
4. Palm O. Moum B, Jahnsen J, Gran JT (2001) The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population based study (the IBSEN study). Rheumatology 40:1256-1261
5. Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23:29-34
6. Badelon I (1999) Eye and spondyloarthropathies. Rev Prat 49:1995-1998
7. Udvardy M, Altorjay I, Palatka K (2001) Hematologic aspects of inflammatory bowel disease. Orv Hetil 142:883-886
8. Ricart E, Panaccione R, Loftus EV et al (2001) Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722-729
9. D'haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopie and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116: 1029-1035
10. Targan SR, Hanauer SB, Van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 337:10235
11. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
12. Ellman MH, Hanauer S, Sitrin M et al (2001) Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 7:67-71
13. Tan MH, Gordon M, Lebwohl O et al (2001) Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 37:930-933
14. Hughes AP, Jackson JM, Callen JP (2000) Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284:1546-1548
15. Yoshida EM (1999) The Crohn's disease activity index, its derivatives and the inflammatory bowel disease questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 13:65-73
16. Harvey RF, Bradshaw JM (1980) Measuring Crohn's disease activity. Lancet 1:1134-1135
17. Van Deventer SJ (1999) Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther [Suppl 4]:3-8
18. Toussirot E, Wendling D (2001) Therapeutic advances in ankylosing spondylitis. Expert Opin Invest Drugs 10:21-29
19. Baeten D, Kruithof E, Van den Bosch F et al (2001) Immunomodulatory effects of anti-tumor necrosis factor a therapy on synovium in spondyloarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 44:186-195
20. Brandt J, Haibel H, Reddig J et al (2002) Successful short-term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29:118-122
21. Keyser FD, Mielants H, Veys EM (2001) Current use of biological for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2:85-93
22. Taylor PC, Williams RO, Maini RN (2001) Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 13:611-616
23. Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352
24. Van den Bosch F, Kruithof E, Baeten D et al (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428-433
25. Stone M, Salonen D, Lax M et al (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28:1605-1614
26. Hadi A, Hickling P, Brown M, Al-Nahhas A (2002) Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology (Oxford) 41:114-116
27. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187-1193
28. Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959-965
29. Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med 346:1349-1356